Robert Hazlett
Stock Analyst at BTIG
(0.56)
# 3,973
Out of 4,944 analysts
23
Total ratings
33.33%
Success rate
-23.84%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.95 | +245.32% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $23.60 | +154.24% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.53 | +2,536.53% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $6.75 | +14,714.81% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $105.23 | -6.87% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $8.21 | +630.82% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $4.22 | +1,392.89% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $7.54 | +284.62% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.33 | +1,954,787.22% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $3.32 | +80.72% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $12.25 | +46.94% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.95
Upside: +245.32%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $23.60
Upside: +154.24%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.53
Upside: +2,536.53%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $6.75
Upside: +14,714.81%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $105.23
Upside: -6.87%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $8.21
Upside: +630.82%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $4.22
Upside: +1,392.89%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $7.54
Upside: +284.62%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.33
Upside: +1,954,787.22%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $3.32
Upside: +80.72%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $12.25
Upside: +46.94%